Estrogens, Conjugated Synthetic A: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Estrogens, Conjugated Synthetic A. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Palpitations | 1% |
| Digestive | 1% |
| Weight increase | 1% |
| Arthralgia | 1% |
| Paresthesia | 1% |
| Vertigo | 1% |
| Rhinitis | 1% |
| Asthenia | 0.7731% |
| Musculoskeletal | 0.7582% |
| Pain abdominal | 0.7159% |
| Anxiety | 0.6179% |
| Headache | 0.5748% |
| Insomnia | 0.4839% |
| Nausea | 0.4374% |
| Vasodilations | 0.4324% |
| Body as a whole | 0.4275% |
| Respiratory | 0.4173% |
| Neurological | 0.4044% |
| Vaginitis | 0.3632% |
| Pharyngitis | 0.3581% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Cenestin therapy is indicated for the: 1. Treatment of moderate-to-severe vasomotor symptoms associated with the menopause. 0.45 mg Cenestin 0.625 mg Cenestin 0.9 mg Cenestin 1.25 mg Cenestin 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 0.3 mg Cenestin
Medical disclaimer: Always consult a qualified healthcare professional about any medication.